First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
- Ruiz-Morales, Jose Manuel
- Swierkowski, Marcin
- Wells, J Connor
- Fraccon, Anna Paola
- Pasini, Felice
- Donskov, Frede
- Bjarnason, Georg A
- Lee, Jae-Lyun
- Sim, Hao-Wen
- Sliwczynsk, Andrzej
- Ptak-Chmielewska, Aneta
- Teter, Zbigniew
- Beuselinck, Benoit
- Wood, Lori A
- Yuasa, Takeshi
- Pezaro, Carmel
- Rini, Brian I
- Szczylik, Cezary
- Choueiri, Toni K
- Heng, Daniel YC
Publication date
September 2016
DOI Publisher
Elsevier BV Journal
European Journal of CancerAbstract
Sunitinib (SU) and pazopanib (PZ) are standards of care for first-line treatment of metastatic renal cell carcinoma (mRCC). However, how the efficacy of these drugs translates into effectiveness on a population-based level is unknown.publisher: Elsevier articletitle: First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium journaltitle: European Journal of Cancer articlelink: http://dx.doi.org/10.1016/j.ejca.2016.06.016 content_type: article copyright: © 2016 Elsevier Ltd. All rights reserved.status: publishe
Add to ORKG